Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for chemoradiotherapy-induced thrombocytopenia in cervical cancer
ChiCTR2400091718Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in Thrombocytopenia, sponsored by Sichuan Cancer Hospital. Primary endpoint: Proportion of patients with platelet count at least 100 × 10^9/L within 3 weeks after treatment with romiplostim N01. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2400091718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091718.